CA2744055A1 - Polypeptides, domaines variables d'anticorps et antagonistes - Google Patents

Polypeptides, domaines variables d'anticorps et antagonistes Download PDF

Info

Publication number
CA2744055A1
CA2744055A1 CA2744055A CA2744055A CA2744055A1 CA 2744055 A1 CA2744055 A1 CA 2744055A1 CA 2744055 A CA2744055 A CA 2744055A CA 2744055 A CA2744055 A CA 2744055A CA 2744055 A1 CA2744055 A1 CA 2744055A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
variable domain
single variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2744055A
Other languages
English (en)
Inventor
Ian Richard Catchpole
Fiona Cook
Gerald Wayne Gough
Laurent Jespers
Michael Steward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/323,632 external-priority patent/US20090148437A1/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CA2744055A1 publication Critical patent/CA2744055A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
CA2744055A 2008-11-26 2009-11-04 Polypeptides, domaines variables d'anticorps et antagonistes Abandoned CA2744055A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/323,632 2008-11-26
US12/323,632 US20090148437A1 (en) 2007-06-06 2008-11-26 Polypeptides, antibody variable domains & antagonists
PCT/EP2009/064654 WO2010060768A1 (fr) 2008-11-26 2009-11-04 Polypeptides, domaines variables d'anticorps et antagonistes

Publications (1)

Publication Number Publication Date
CA2744055A1 true CA2744055A1 (fr) 2010-06-03

Family

ID=41507943

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2744055A Abandoned CA2744055A1 (fr) 2008-11-26 2009-11-04 Polypeptides, domaines variables d'anticorps et antagonistes

Country Status (11)

Country Link
EP (1) EP2356147A1 (fr)
JP (1) JP2012509852A (fr)
KR (1) KR20110091777A (fr)
CN (1) CN102224169A (fr)
AU (1) AU2009319175A1 (fr)
BR (1) BRPI0921319A2 (fr)
CA (1) CA2744055A1 (fr)
IL (1) IL212333A0 (fr)
MX (1) MX2011005540A (fr)
WO (1) WO2010060768A1 (fr)
ZA (1) ZA201103588B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
WO2011026948A1 (fr) 2009-09-03 2011-03-10 Ablynx N.V. Formulations stables de polypeptides et leurs utilisations
EP2538965B1 (fr) 2010-02-25 2017-04-12 Schepens Eye Research Institute Compositions thérapeutiques pour le traitement du syndrome de l' oeil sec
EP2643351A1 (fr) * 2010-11-24 2013-10-02 Glaxo Group Limited Protéines multispécifique se liant à un antigène et ciblant hgf
SG10201608703SA (en) 2012-11-08 2016-12-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
ES2875878T3 (es) 2013-11-18 2021-11-11 Formycon Ag Composición farmacéutica de un anticuerpo anti-VEGF
ES2756275T3 (es) 2014-11-07 2020-04-27 Sesen Bio Inc Anticuerpos contra IL-6 mejorados

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
TW200730539A (en) * 2005-12-01 2007-08-16 Domantis Ltd Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
EP1966242A1 (fr) * 2005-12-06 2008-09-10 Domantis Limited Ligands presentant une specificite de liaison avec l'egfr et/ou le vegf et leurs procedes d'utilisation
EA017417B1 (ru) * 2006-02-01 2012-12-28 Сефалон Астралия Пти Лтд. КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ
KR20100040840A (ko) * 2007-06-06 2010-04-21 도만티스 리미티드 폴리펩티드，항체 가변 도메인 및 길항제
KR20100018040A (ko) * 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery

Also Published As

Publication number Publication date
JP2012509852A (ja) 2012-04-26
CN102224169A (zh) 2011-10-19
MX2011005540A (es) 2011-06-21
IL212333A0 (en) 2011-06-30
BRPI0921319A2 (pt) 2018-10-16
ZA201103588B (en) 2012-01-25
EP2356147A1 (fr) 2011-08-17
WO2010060768A1 (fr) 2010-06-03
AU2009319175A1 (en) 2010-06-03
KR20110091777A (ko) 2011-08-12

Similar Documents

Publication Publication Date Title
US20110256122A1 (en) Polypeptides, antibody variable domains & antagonists
JP6796184B2 (ja) 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
CA2744055A1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
AU2005311101B8 (en) Anti-IL-IRI single domain antibodies and therapeutic uses
AU2006321364B2 (en) Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
AU2006321367B2 (en) Competitive domain antibody formats that bind Interleukin 1 Receptor type 1
US20120076787A1 (en) Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye
US20100291103A1 (en) Polypeptides, antibody variable domains and antagonists
JP2010528646A (ja) ポリペプチド、抗体可変ドメイン、およびアンタゴニスト
US20110301335A1 (en) Anti-tnfr1 polypeptides, antibody variable domains & antagonists
US20120107330A1 (en) Antagonists, uses & methods for partially inhibiting tnfr1
US8092800B2 (en) Antibodies against Candida antigens
EP2493504B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables d'anticorps, et antagonistes
US9028817B2 (en) Stable anti-TNFR1 polypeptides, antibody variable domains and antagonists
MX2008006882A (en) Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20131105